Arcturus Therapeutics Holdings Inc. (ARCT)


Stock Price Forecast

April 24, 2024


Forecasted Returns

7 Days Predict

30 Days Predict

90 Days Predict


Forecasted Market-Excess Returns

7 Days Predict

30 Days Predict

90 Days Predict

Loading Arcturus Therapeutics Holdings Inc. chart...

About the Company

Arcturus Therapeutics Holdings Inc. is an American RNA medicines biotechnology company focused on the discovery, development and commercialization of therapeutics for rare diseases and infectious diseases. Arcturus has developed proprietary lipid nanoparticle RNA therapeutics for nucleic acid medicines including small interfering RNA (siRNA), messenger RNA (mRNA), gene editing RNA, DNA, antisense oligonucleotides, and microRNA. The company develops RNA therapeutics for the treatment of rare diseases such as ornithine transcarbamylase deficiency, and respiratory diseases such as cystic fibrosis. As of 2021, vaccine medicines include a vaccine candidate for COVID-19 and an influenza vaccine in the preclinical development phase.

Sector

Life Sciences

Industry

Pharmaceutical Preparations

Employees

184

Exchange

Nasdaq

$358M

Total Revenue

184

Employees

$724M

Market Capitalization

-17.09

Price/Earning ratio

Fundamental Data and Insider Transactions (Quarterly data) Full Screen

Loading the fundamentals chart...

Latest $ARCT News

Arcturus Therapeutics to Report First Quarter Financial Results and Provide Corporate Update on May 8, 2024

11h ago, source: Business Wire

Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a global messenger RNA medicines company ...

ARCT Arcturus Therapeutics Holdings Inc.

2d ago, source: Seeking Alpha

Arcturus Therapeutics Holdings Inc., a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver ...

Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Q4 2023 Earnings Call Transcript

1mon ago, source: InvestingChannel on MSN

Arcturus Therapeutics Holdings Inc. beats earnings expectations. Reported EPS is $-0.32, expectations were $-1.69. ARCT isn't ...

Arcturus Therapeutics Holdings, Inc.

2mon ago, source: CNN

Arcturus Therapeutics Holdings, Inc. operates as a late-stage clinical mRNA medicines and vaccine company, which engages in the development of infectious disease vaccines and significant ...

Arcturus Therapeutics Holdings Inc

4d ago, source: Morningstar

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Arcturus Therapeutics Holdings Inc.

8d ago, source: Wall Street Journal

1 Day ARCT -8.26% DJIA -0.12% Russell 2K -0.99% Health Care/Life Sciences -0.42% ...

Arcturus Therapeutics Holdings Inc.

3mon ago, source: Barron's

Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International ...

Latest Neutral (free) Forecasts

STRONG BUY BUY NEUTRAL SELL STRONG SELL ALL

Loading the latest forecasts...

My Portfolio

Loading your portfolio...